TRV GP Iv, LLC

In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 8, 2025), TRV GP Iv, LLC reported 3 stock positions worth $163.3 million. Its top holding was Tango Therapeutics (TNGX) at 52.9% of the portfolio, followed by Maze Therapeutics (MAZE, 45.6%) and Pliant Therapeutics (PLRX, 1.5%). Its holdings were unchanged from Q1 2025.

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001688325
Portfolio Value
$163.3M (Q2 2025)
SEC Filing
0000950123-25-007372 ↗ filed Aug 8, 2025

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $206.4M Q1 2024 Q2 2024: $202.2M Q2 2024 Q3 2024: $162.1M Q3 2024 Q4 2024: $80.2M Q4 2024 Q1 2025: $92.9M Q1 2025 Q2 2025: $163.3M $163.3M Q2 2025 Q3 2025: $274.0M Q3 2025 Q4 2025: $255.1M Q4 2025 Q1 2026: $266.9M Q1 2026 Q2 2026: $253.7M Q2 2026

Holdings 3 stocks · $163.3M
TNGX Tango Therapeutics Inc. 52.85% 16,859,075 $86.3M No change
MAZE Maze Therapeutics Inc. 45.63% 6,073,958 $74.5M No change
PLRX Pliant Therapeutics Inc. 1.51% 2,132,867 $2.5M No change

Portfolio Sells Q1 2025 → Q2 2025
None this quarter.

Portfolio Buys Q1 2025 → Q2 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$253.7MMAZE, TNGX
Q1 2026 2$266.9MMAZE, TNGX
Q4 2025 2$255.1MMAZE, TNGX
Q3 2025 2$274.0MMAZE, TNGX
Q2 2025 3$163.3MTNGX, MAZE, PLRX
Q1 2025 3$92.9MMAZE, TNGX, PLRX
Q4 2024 2$80.2MTNGX, PLRX
Q3 2024 3$162.1MTNGX, PLRX, FULC
Q2 2024 3$202.2MTNGX, PLRX, FULC
Q1 2024 3$206.4MTNGX, PLRX, FULC